FROST (FiRst-line Options for Systemic JIA Treatment) Study
FAMILIES WORK WITH RESEARCHERS TO FIND THE BEST WAY TO TREAT SYSTEMIC JIA
FROST is made possible through support from Genentech and supporters of the CARRA Registry including the Arthritis Foundation (click here for a full list of supporters). Blood sample collection is made possible by the Systemic JIA Foundation.
This study compares the effectiveness of biologic medications (like anakinra, canakinumab and tocilizumab) to non-biologic medications (prednisone, methotrexate) commonly being used to treat patients who newly develop systemic JIA. The treatments are chosen through discussion between the physician, patient and family and patients are followed in the CARRA registry to see how they do
WHO IS INVOLVED?
43 CARRA Registry sites are participating across the US and Canada.
The lead investigators are Yukiko Kimura, MD (Hackensack University Medical Center, NJ) and Timothy Beukelman, MD MCSE (University of Alabama at Birmingham)
The primary patient partners are Vincent Del Gaizo (parent of systemic JIA patient) and Marian Jelinek (young adult systemic JIA patient)
The coordinating center is the Duke Clinical Research Institute (DCRI)
WHY THIS IS IMPORTANT
There are new and effective treatments for systemic JIA, but we don’t know if using these treatments first line makes an important difference in how quickly the patients get better, how they do in the long term, or is safer.
Our patient partners are primary members of our study team and help us improve how the study is conducted. We use tools such as videos, electronic questionnaires and apps to report symptoms from home to make it easier to participate in the study.
This is the first study to look at initial treatment in systemic JIA.